# Wuxi NextCODE Genomics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/wuxi-nextcode-genomics

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.wuxinextcode.cn
- Total disclosed funding: $455M
- Latest round: Series C (Nov 27, 2018)
- Investors on record: 8

## About

Established in 2011 and headquartered in Shanghai, China, Wuxi NextCODE Genomics (formerly known as WuXi Genome Center) is a clinical diagnostics company that provides sequencing solutions for personalized medicine. In 2015, the entity was merged with NextCODE Health.

## Funding rounds

- Series C, Nov 27, 2018, $200M — Hong Shan, Temasek Holdings, Ireland Strategic Investment Fund, YF Capital
- Series B, Sep 7, 2017, $165M — Hong Shan, Temasek Holdings, YF Capital, 3W Partners
- Series B, May 1, 2017, $75M — Temasek Holdings, Amgen Ventures, YF Capital, 3W Partners
- Series A, Oct 23, 2013, $15M — ARCH Venture Partners, Polaris Partners

## Investors

- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series A
- Polaris Partners (https://capitalatlas.ai/funds/polaris-partners) — Series A
- Temasek Holdings — Series B, Series C
- Amgen Ventures (https://capitalatlas.ai/funds/amgen-ventures) — Series B
- YF Capital (https://capitalatlas.ai/funds/yf-capital) — Series B, Series C
- 3W Partners (https://capitalatlas.ai/funds/3w-partners) — Series B
- Hong Shan — Series B, Series C
- Ireland Strategic Investment Fund — Series C